Bristol Myers Squibb Co. said about 5% of Opdivo patients are taking a new, easier-to-use version of the blockbuster cancer drug and said it’s on course to meet the company’s goal of adoption by at ...

KYOTO--Researchers at Kyoto University have identified a new approach to a type of colorectal cancer that is resistant to ...

BMY shares have surged in the past six months, driven by Opdivo, Reblozyl and a guidance raise, as growth drugs offset ...

BMS looks forward to pivotal readouts for six assets in 2026, ensuring profits after patent expiries for Opdivo and Eliquis.

(Reuters) -Bristol Myers Squibb beat Wall Street estimates for third-quarter revenue on Thursday, as strong growth of its cancer immunotherapy and blood thinner Eliquis helped the drugmaker overcome a ...

Opdivo showed superior long-term efficacy over Yervoy in resected stage 3B-4 melanoma, with improved RFS and DMFS outcomes. Median OS and MSS were not reached, but data favored Opdivo, suggesting a ...

Bristol Myers (BMY) has a strong oncology portfolio comprising blockbuster immune-oncology drug Opdivo, Opdivo Qvantig, and Yervoy, among others. Opdivo is a key drug in BMY’s Growth Portfolio that is ...

Bristol Myers BMY has a broad oncology portfolio, which includes blockbuster immuno-oncology drugs, Opdivo, Opdivo Qvantig and Yervoy, among others. Among these, Opdivo (nivolumab) is the top revenue ...

The Delhi High Court has allowed Zydus Lifesciences to sell its nivolumab biosimilar, citing public interest, while directing ...

Could the pharmaceutical giant turn things around next year? Let's find out whether Bristol Myers Squibb is a buy, sell, or ...

If you are wondering whether Bristol-Myers Squibb is priced attractively right now, you are not alone. This article walks ...